Iranian Journal of Basic Medical Sciences

Iranian Journal of Basic Medical Sciences

Inflammasome-associated pyroptosis and tumor angiogenesis in prostate cancer

Articles in Press

Document Type : Review Article

Authors
Hamzeh J. Alameer 1
Rafid Kamal Jameel 2
Mahzuna Nasretdinova 3
Ravshan Sultanov 4
Djamila Polatova 5
Mohammed Abdul Alaal 6
Navin Kumar Tailor 7
Ritesh Singh 8
1 Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan
2 College of Pharmacy, Alnoor University, Mosul, Iraq
3 Department of Otorhinolaryngology, Samarkand State Medical University, Samarkand, Uzbekistan
4 Department of Medical Fundamental Sciences, Termez University of Economics and Service, Termez, Uzbekistan
5 Scientific-Practical Medical Center for Pediatric Oncology, Hematology and Immunology, Tashkent, Uzbekistan
6 Department of Pharmacy, College of Pharmacy, The Islamic University, Najaf, Iraq
7 University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India
8 Center for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India
10.22038/ijbms.2026.95483.20581
Abstract
Tumor angiogenesis in prostate cancer is increasingly recognized as a dynamic process shaped by inflammatory signaling, endothelial adaptation, and microenvironmental stress. However, the mechanistic contribution of inflammasome-associated pyroptosis to vascular remodeling remains insufficiently integrated, particularly in relation to functional vascular endpoints such as perfusion, permeability, and therapeutic delivery. This review critically evaluates current evidence linking inflammasome activation and pyroptotic signaling to angiogenic remodeling within prostate tumor microenvironments. Current mechanistic and translational studies addressing inflammasome signaling, gasdermin-associated membrane permeabilization, endothelial activation, cytokine amplification, and vascular remodeling were synthesized with emphasis on spatial heterogeneity, hypoxia-associated stress, and methodological limitations. Available evidence suggests that inflammasome-associated pathways may influence angiogenic remodeling through interleukin-1-mediated endothelial activation, myeloid-cell inflammatory amplification, extracellular signaling, and context-dependent pyroptotic responses. Emerging findings further indicate that vascular consequences vary according to metabolic stress, compartment-specific signaling, and local inflammatory states. However, interpretation remains limited by reliance on static tissue measurements, bulk inflammatory analyses, and indirect vascular readouts that insufficiently distinguish inflammasome priming from terminal pyroptotic execution. Inflammasome-associated pyroptotic signaling may contribute to vascular remodeling in prostate cancer under defined biological conditions, although substantial mechanistic and translational uncertainties remain. Improved integration of spatial inflammatory profiling and functional vascular assessment may support more precise therapeutic targeting and clinically relevant vascular interpretation in heterogeneous prostate tumor microenvironments.
Keywords
Angiogenesis
Endothelium
Gasdermin D
Inflammasomes
Interleukin-1beta
Prostatic
Neoplasms Pyroptosis
Tumor microenvironment
Subjects
1. Børretzen A, Reisæter LAR, Ringheim A, Gravdal K, Haukaas SA, Fasmer KE, et al. Microvascular proliferation is associated with high tumour blood flow by mpMRI and disease progression in primary prostate cancer. Sci Rep 2023; 13: 17949. 
2. Yang S, Fang Y, Ma Y, Wang F, Wang Y, Jia J, et al. Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice. Clin Transl Med 2025; 15: e70313. 
3. Xiao Y, Hassani M, Moghaddam MB, Fazilat A, Ojarudi M, Valilo M. Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis,  metastasis, and drug resistance. Med Oncol 2025; 42: 108. 
4. Butler MB, Papageorgiou G, Kanoulas ED, Voulgaridou V, Wijkstra H, Mischi M, et al. Mapping of prostate cancer microvascular patterns using super-resolution ultrasound imaging. Eur Radiol Exp 2025; 9: 25. 
5. Dubey SR, Turnbull C, Pandey A, Zhao A, Kurera M, Al-Zidan R, et al. Molecular mechanisms and regulation of inflammasome activation and signaling: Sensing of pathogens and damage molecular patterns. Cell Mol Immunol 2025; 22: 1313–1344. 
6. Karpiuk KR, Młynarczyk G, Matowicka-Karna J, Darewicz B. Emerging biomarkers in urological cancers: Angiogenesis and damage-associated molecular pattern signaling. Int J Mol Sci 2025; 26: 9130. 
7. Sharma U, Sahu A, Shekhar H, Sharma B, Haque S, Kaur D, et al. The heat of the battle: Inflammation’s role in prostate cancer development and  inflammation-targeted therapies. Discov Oncol 2025; 16: 108. 
8. Wang M, Xiao Y, Miao J, Zhang X, Liu M, Zhu L, et al. Oxidative stress and inflammation: Drivers of tumorigenesis and therapeutic opportunities. Antioxidants. 2025; 14: 735. 
9. Teng Q, Wang N, Lei H, Tong T, Guan Y, Huang M, et al. TGF-β3 promotes vascular normalization of prostate cancer to potentiate immunotherapy and chemotherapy. Cancer Immunol Immunother 2025; 74: 268. 
10. Alishvandi A, Aram C, Shahrivar FF, Kesharwani P, Sahebkar A. Pyroptosis in cancer therapy: A double-edged sword for immune activation and tumor progression. Mol Cancer 2025; 24: 297.
11. Liu X, Wang Z, Zhu H, Han Y, Ji Q. Inflammation and cancer: Molecular mechanisms and therapeutic targets. MedComm 2026; 7: e70605. 
12. Johnson DE, Cui Z. Triggering pyroptosis in cancer. Biomolecules 2025; 15: 348. 
13. Huang C, Li J, Wu R, Li Y, Zhang C. Targeting pyroptosis for cancer immunotherapy: Mechanistic insights and clinical perspectives. Mol Cancer 2025; 24: 131. 
14. Malvankar S, Jaiswal P, Bhat PP, Mehto S. Regulation of cancer by inflammasomes: From inflammation to tumorigenesis. Front Immunol 2025; 16: 1611719. 
15. Singh V, Ubaid S, Kashif M, Singh T, Singh G, Pahwa R, et al. Role of inflammasomes in cancer immunity: Mechanisms and therapeutic potential. J Exp Clin Cancer Res 2025; 44: 109. 
16. Huang L, Chen X, Liu R, Nan D, Bao W, Yang L, et al. Targeting inflammasomes as an immunotherapeutic strategy for cancer. J Transl Med 2025; 23: 634. 
17. Bhatti GK, Ahmed I, Verma A, Sidhu IS, Bhatti JS, Kaura KS. Inflammation beyond the prostate: The role of systemic inflammatory disorders in  prostate carcinogenesis. Cureus 2025; 17: e99640. 
18. Han Y, Zhu B, Meng S. Endothelial cell in tumor angiogenesis: Origins, mechanisms, and therapeutic  implication. Genes Dis 2025; 12: 101611. 
19. Hernández-Camarero P, Toledo B, Diaz-Ruano AB, González-Titos A, García-Ortega MB, Perán M. What is the impact of endothelial-to-mesenchymal transition in solid tumours: a  qualitative systematic review and quantitative meta-analysis. Int J Biol Sci 2025; 21: 2155-2178. 
20. Liu X, Zhang J, Yi T, Li H, Tang X, Liu D, et al. Decoding tumor angiogenesis: Pathways, mechanisms, and future directions in anti-cancer strategies. Biomark Res 2025; 13: 62. 
21. Leach D, Chatterjee N, Spahr K, De Almeida GS, Varela‐Carver A, Shah TT, et al. Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis. Mol Oncol 2025; 19: 2797-2821. 
22. Oria V, Castro JL, De Pina Roque J, Martinez AG, Jørgensen FI, Lukassen M, et al. Crosstalk between tumor endothelial cells and cancer cells is important for metastasis initiation. Cell Commun Signal 2025; 23: 443. 
23. Muhetarijiang M, Zhu P, Zhang H, Sun X, Wu Y, Xu Q, et al. A pan-cancer single-cell analysis reveals the effect of PD-1 blockades on tumor angiogenesis by inhibiting the endothelial CXCL12-CXCR4 axis. Cancer Immunol Immunother 2025; 74: 330. 
24. Yang J, Wu W, Tang X. Integration of single-cell and bulk transcriptome to reveal an endothelial transition signature predicting bladder cancer prognosis. Biology (Basel) 2025; 14: 486. 
25. Santos M, Koushyar S, Dart D, Uysal-Onganer P. From hypoxia to bone: Reprogramming the prostate cancer metastatic cascade. Int J Mol Sci 2025; 26: 7452. 
26. Zhang Y, Wang J, He M, Liu J, Zhao J, He J, et al. Hypobaric hypoxia-driven energy metabolism disturbance facilitates vascular endothelial dysfunction. Redox Biol 2025; 84: 103675. 
27. Bakleh MZ, Al Haj Zen A. The distinct role of HIF-1α and HIF-2α in hypoxia and angiogenesis. Cells 2025; 14: 673. 
28. Liu L, Yu J, Liu Y, Xie L, Hu F, Liu H. Hypoxia-driven angiogenesis and metabolic reprogramming in vascular tumors. Front cell Dev Biol 2025; 13: 1572909. 
29. Gatto C, Rusciano M, Sorriento D, Di Pietro P, Abate AC, Visco V, et al. Mitochondrial accumulation of GRK2 as a protective mechanism against hypoxia-induced endothelial dysfunction. Cell Death Discov 2025; 11: 324.
30. Tóth A, Jeney V. Hypoxia-induced changes in endothelial cell phenotype and function. Antioxid Redox Signal 2025; 43: 849-868. 
31. She H, Zheng J, Zhao G, Du Y, Tan L, Chen ZS, et al. Arginase 1 drives mitochondrial cristae remodeling and PANoptosis in ischemia/hypoxia-induced vascular dysfunction. Signal Transduct Target Ther 2025; 10: 167.
32. Arndt P, Boewe S, Brüggemann J, Garcia-Garcia B, Yakupov R, Vockert N, et al. Putamen vascularization on high-resolution 7T MRI is associated with perfusion and cognitive performance in cerebral small vessel disease. Neuroimage 2025; 319: 121426.
33. Lee JD, Kumar A, Mathur T, Jain A. Vascular architecture-on-chip: Engineering complex blood vessels for reproducing physiological and heterogeneous hemodynamics and endothelial function. Lab Chip 2025; 25: 2620–2631.
34. Liberale L, Duncker D, Hausenloy D, Kraler S, Bøtker H, Podesser B, et al. Vascular (dys)function in the failing heart. Nat Rev Cardiol 2025; 22: 728-750.
35. Erasha A, El-Gendy H, Aly A, Fernández-Ortiz M, Sayed R. The role of the tumor microenvironment (TME) in advancing cancer therapies: immune system interactions, tumor-infiltrating lymphocytes (TILs), and the role of exosomes and inflammasomes. Int J Mol Sci 2025; 26: 2716. 
36. Krossa S, Andersen M, Sandholm E, Wess M, Kiviaho A, Sharma A, et al. Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment. Nat Commun 2025; 16: 10160.
37. Shakerdi A, Finnegan E, Sheng YY, Vidovic K, Logan J, Ward M, et al. Crosstalk between inflammasome signalling and epithelial-mesenchymal transition in cancer and benign disease: Mechanistic insights, context-dependence, and therapeutic opportunities. Cells 2025; 14: 1594.
38. Liu S, Zhang J. A comprehensive analysis of the relationship between inflammasomes and autophagy in human tumors: Recent developments. J Cell Commun Signal 2025; 19: e70035.
39. Chen S, Deng B, Liu Y, Xie L, Xu J, Hu R, et al. The CTSZ-TRA2A-IL32 axis defines a targetable macrophage-dependent pathway in metastatic prostate cancer. J Transl Med 2025; 23: 865.
40. Colarusso C, Terlizzi M, Di Caprio S, Falanga A, D’Andria E, Di Villa Bianca R d’Emmanuele, et al. Role of the AIM2 inflammasome in cancer: potential therapeutic strategies. Biomedicines 2025; 13: 395. 
41. Liu X, He H, Qi M, Jiang Z, Lin B, Wang X, et al. A small molecule directly targets NLRP3 to promote inflammasome activation and antitumor immunity. Cell Death Dis 2025; 16: 252.
42. Wang H, Li, Su W, Liu Y, Xie N, Liu J. NLRP3 inflammasome in health and disease (Review). Int J Mol Med 2025; 55: 48.
43. Ghoreifi A, Alshalalfa M, Davicioni E, Spratt DE, Karnes RJ, Purves JT, Hughes FM Jr, Moul JW, Abern MR. Characterizing the activity of inflammasome-related genes and their association with oncological outcomes in prostate cancer. Prostate 2026; 86: 1224-1232.
44. Zhuo Z, Xie Y, Zou H, Tan B, Dong Q, Dong B, et al. Review: Progress of the NLRP3 inflammasome in tumours and perspectives for cholangiocarcinoma. Cell Commun Signal 2025; 23: 405. 
45. Feng S, Wierzbowski M, Hrovat-Schaale K, Dumortier A, Zhang Y, Zyulina M, et al. Mechanisms of NLRP3 activation and inhibition elucidated by functional analysis of disease-associated variants. Nat Immunol 2025; 26: 511-523.
46. Jiang J, Yan Y, Yang C, Cai H. Immunogenic cell death and metabolic reprogramming in cancer: Mechanisms, synergies, and innovative therapeutic strategies. Biomedicines 2025; 13: 950.
47. Cheng X, Wang Y, Johnson B, You M. Mitochondria-targeted strategies in tumor immunity. Front Immunol 2025; 16: 1646138.
48. Xu X, Pang Y, Fan X. Mitochondria in oxidative stress, inflammation and aging: From mechanisms to therapeutic advances. Signal Transduct Target Ther 2025; 10: 190. 
49. Zhu L, Guo Z, Luo Y, Huang H, Zhang K, Duan B, et al. High‐efficiency carriers’ separation strategy based ultrasmall‐bandgap CuWO4 sono‐enhances GSH antagonism for cuproptosis cascade immunotherapy. Adv Sci 2025; 12: e00576.
50. Liang X, Weng J, You Z, Wang Y, Wen J, Xia Z, et al. Oxidative stress in cancer: From tumor and microenvironment remodeling to therapeutic frontiers. Mol Cancer 2025; 24: 219.
51. Yang Q, Cui M, Wang J, Zhao Y, Yin W, Liao Z, et al. Circulating mitochondrial DNA promotes M2 polarization of tumor associated macrophages and HCC resistance to sorafenib. Cell Death Dis 2025; 16: 153.
52. Deng X, Huang S. Microbiome-macrophage crosstalk in the tumor microenvironment: Implications for oral squamous cell carcinoma progression and therapy. Front Immunol 2025; 16: 1651837. 
53. Zhao Y, Yang Z, Wu D, Zhao H. Dissecting the intratumoral microbiome landscape in lung cancer. Front Immunol 2025; 16: 1614731. 
54. Nie C, Qi Y, Wang T, Shan Y, Xie C, Jiang Z, et al. Nanodrug-based therapeutic interventions for tumor-associated microbiota modulation. J Control Release 2025; 387: 114196
55. Zhang Y, Chen XX, Chen R, Li L, Ju Q, Qiu D, et al. Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer. Clin Transl Med 2025; 15: e70170. 
56. Zhang W, Xiang Y, Ren H, Liu Y, Wang Q, Ran M, et al. The tumor microbiome in cancer progression: Mechanisms and therapeutic potential. Mol Cancer 2025; 24: 195. 
57. Cui X, Liu S, Song H, Xu J, Sun Y. Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Mol Cancer 2025; 24: 111.
58. Zhao F, Jiang X, Li Y, Huang T, Xiahou Z, Nie W, et al. Characterizing tumor biology and immune microenvironment in high-grade serous ovarian cancer via single-cell RNA sequencing: Insights for targeted and personalized immunotherapy strategies. Front Immunol 2025; 15: 1500153.
59. Benimam M, Meas-Yedid V, Mukherjee S, Frafjord A, Corthay A, Lagache T, et al. Statistical analysis of spatial patterns in tumor microenvironment images. Nat Commun 2025; 16: 3090.
60. Erreni M, Fumagalli M, Marozzi M, Leone R, Parente R, D’Anna R, et al. From surfing to diving into the tumor microenvironment through multiparametric imaging mass cytometry. Front Immunol 2025; 16: 1544844.
61. Chai Z, Zhou Y, Hossain S, Huynh K, Hajimirzaei S, Zhang Y, et al. Cardiolipin’s multifaceted role in immune response: A focus on interacting proteins. Front Immunol 2025; 16: 1680326.
62. Paik S, Kim JK, Shin HJ, Park EJ, Kim IS, Jo EK. Updated insights into the molecular networks for NLRP3 inflammasome activation. Cell Mol Immunol 2025; 22: 563-596.
63. Chen Z, Behrendt R, Wild L, Schlee M, Bode C. Cytosolic nucleic acid sensing as driver of critical illness: mechanisms and advances in therapy. Signal Transduct Target Ther 2025; 10: 90.
64. Zou C, Jiang S, Li H, Zhao K, Cao D, Yang G. The NLRP3 inflammasome: Mechanisms of activation, regulation, and therapeutic  opportunities. MedComm 2026; 7: e70660. 
65. Duncan JA, Canna SW. The NLRC4 Inflammasome. Immunol Rev 2018; 281: 115–123. 
66. Boncompagni C, Giacovazzi S, Perrone M, Missiroli S, Righes G, Pinton P, et al. Radiation meets inflammation: NLRP3 inflammasome at the core of radiation-induced  cardiac injury. J Transl Med 2025; 23: 1330. 
67. Liao X, Wang Y, Zhang Z, Qu X, Zhou G. Bidirectional regulation of NLRP3 inflammasome and mitochondrial quality control  in sepsis: mechanisms and therapeutic implications. Mediators Inflamm 2026; 2026: 3168669. 
68. Xu J, Ding L, Mei J, Hu Y, Kong X, Dai S, et al. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Ther 2025; 10: 268.
69. Alanazi A, Selim M, Liu F, Zhang D, Narayanan S, Somanath P. Pre‐existing diabetes alters pulmonary inflammatory gene expression priming for injury. FASEB J 2025; 39: e70804. 
70. Valencia J, Yáñez R, Muntión S, Fernández-García M, Martín-Rufino J, Zapata A, et al. Improving the therapeutic profile of MSCs: Cytokine priming reduces donor-dependent heterogeneity and enhances their immunomodulatory capacity. Front Immunol 2025; 16: 1473788.
71. Cheng H, Nan F, Ji N, Xiao, Zhang J, Liang H, et al. Regulatory T cell therapy promotes TGF-β and IL-6-dependent pro-inflammatory Th17 cell generation by reducing IL-2. Nat Commun 2025; 16: 7644.
72. Song B, Guo W, He Y, Yao X, Sun J, Wang S. Targeting immune cell migration as therapy for inflammatory disease: A review. Front Immunol 2025; 16: 1650760.
73. Lee C, Park YW, Park MH, Lee YJ, Rhee I. Regulatory T cells and their role in inflammatory bowel disease: molecular targets, therapeutic strategies and translational advances. Biochem Pharmacol 2025; 239: 117087.
74. Li Y, Guo B. GSDMD-mediated pyroptosis: Molecular mechanisms, diseases and therapeutic targets. Mol Biomed 2025; 6: 11. 
75. Tian S, Zhang Y, Liu C, Zhang H, Lu Q, Zhao Y, et al. Double-edged mitophagy: Balancing inflammation and resolution in lung disease. Clin Sci (Lond) 2025; 139: 1047-1072.
76. Shojaee F, Azadian E, Wong MX, Xiuquan, Rickard J, Pang J, et al. NLRP3 inflammasome–driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors. Sci Adv 2025; 11: eadv0079.
77. Zhang H, Zhao T, Gu J, Tang F, Zhu L. Gut microbiota and inflammasome-mediated pyroptosis: A bibliometric analysis from 2014 to 2023. Front Microbiol 2025; 15: 1413490. 
78. Margheritis E, Gehle N, Cosentino K. Gasdermins: Multifunctional effectors of membrane permeabilization across cellular compartments. FEBS J 2025 ; 292: 5899-5920 . 
79. Wang K, Luo H, Liu L, Gao H, Song Y, Li D. Blockade of IL-1 family cytokines in the treatment of rheumatoid arthritis. Front Pharmacol 2025; 16: 1577628.
80. Nguyen T, Kwon SJ, Hurh S, Kale A, Cho JM, Nada H, et al. LMT2368 (1-(4-Chlorophenyl)-3-(3-fluoro-5-(trifluoromethyl)phenyl)urea) negatively regulates inflammation by inhibiting NLRP3 inflammasome activation. Pharmaceutics 2025; 17: 1241. 
81. Gunji Y, Matsumura T, Karasawa T, Komada T, Baatarjav C, Komori S, et al. IL-33-primed NLRP3 inflammasome in basophils drives IL-1β production and initiates atopic dermatitis inflammation. Cell Death Discov 2025; 11: 346. 
82. Casey A, Ryan D, Prag H, Chowdhury S, Marques E, Turner K, et al. Pro-inflammatory macrophages produce mitochondria-derived superoxide by reverse electron transport at complex I that regulates IL-1β release during NLRP3 inflammasome activation. Nat Metab 2025; 7: 493-507.
83. M Bader S, Scherer L, Schaefer J, Cooney JP, Mackiewicz L, Dayton M, et al. IL-1β drives SARS-CoV-2-induced disease independently of the inflammasome and  pyroptosis signalling. Cell Death Differ 2025; 32: 1353-1366. 
84. Grytting V, Kirkerød E, Skuland T, Refsnes M, Lag M, Sadiktsis I, et al. Pro-inflammatory effects of road wear particles and diesel exhaust particles in bronchial epithelial cells and macrophages. Environ Res 2025; 283: 122134.
85. Schachter J, Guijarro A, Angosto-Bazarra D, Pinilla M, Hurtado-Navarro L, Meunier E, et al. Gasdermin D mediates a fast transient release of ATP after NLRP3 inflammasome activation before ninjurin 1-induced lytic cell death. Cell Rep 2025; 44: 115233.
86. Wang C, Dreyer B, Teran E, Ruan J. From pores to rupture: Structural basis and regulation of lytic cell death by gasdermins and NINJ1. J Biol Chem 2025; 301: 110698.
87. Broz P. Pyroptosis: Molecular mechanisms and roles in disease. Cell Res 2025; 35: 334-344. 
88. Yuan Y, Martsch P, Chen X, Martinez E, Li L, Song J, et al. Atrial cardiomyocyte-restricted cleavage of gasdermin D promotes atrial arrhythmogenesis. Eur Heart J 2025; 46: 1250-1262.
89. Ren K, Farrell J, Li Y, Guo X, Xie R, Liu X, et al. Mechanisms of RCD-1 pore formation and membrane bending. Nat Commun 2025; 16: 1011.
90. Zandonadi R, Ramos MC, Elias FTS, Guimarães N. Global insights into cultured meat: Uncovering production processes, potential hazards, regulatory frameworks, and key challenges—a scoping review. Foods 2025; 14: 129.
91. An YW, Li S, Huang X, Chen XS, Xu M, Chen C, et al. Electrospun nanofiber scaffolds loaded with copper oxide for repairing traumatic brain injury through restoring copper homeostasis and regulating pyroptosis pathway. Burn Trauma 2025; 13: 030. 
92. Hong Z, Mo T, Zhou P, Chen J, Li X. Progress of estrogen receptor and spliceosome in endometrial carcinoma. Front Endocrinol (Lausanne) 2025; 16: 1586191.
93. Van Velthoven C, Gao Y, Kunst M, Lee C, McMillen D, Chakka A, et al. Transcriptomic and spatial organization of telencephalic GABAergic neurons. Nature 2025; 647: 143-156. 
94. Porter R, An S, Gavilan M, Nagai M, Murata-Nakamura Y, Zhou B, et al. Coordinated neuron-specific splicing events restrict nucleosome engagement of the LSD1 histone demethylase complex. Cell Rep 2025; 44: 115213. 
95. Cardamone F, Piva A, Löser E, Eichenberger B, Romero-Mulero MC, Zenk F, et al. Chromatin landscape at cis-regulatory elements orchestrates cell fate decisions in early embryogenesis. Nat Commun 2025; 16: 3007.
96. Zhou B, Abbott D. Gasdermins, executors of pyroptosis: A decade in perspective. Annu Rev Pathol Mech Dis 2026; 21: 163-184.
97. Elkayam E, Gervais FG, Wu H, Crackower MA, Lieberman J. New insights into the noncanonical inflammasome point to caspase-4 as a druggable  target. Nat Rev Immunol 2025; 25: 558-568. 
98. Sun J, Yang J, Tao J, Yang Y, Wang R, Zhang H, et al. Delaying pyroptosis with an AI-screened gasdermin D pore blocker mitigates inflammatory response. Nat Immunol 2025; 26: 1660-1672.
99. Yang S, Qi Y, Chen Y, Kong H, Han B, Peng Z, et al. Regulating the balance between GSDMD-mediated pyroptosis and CHMP4B-dependent  cell repair attenuates calcium oxalate kidney stone formation. Int J Biol Sci 2025; 21: 3099-3121. 
100. Rogers C, Erkes DA, Nardone A, Aplin AE, Fernandes-Alnemri T, Alnemri ES. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during  apoptosis and inflammasome activation. Nat Commun 2019; 10: 1689. 
101. Buzas EI. The roles of extracellular vesicles in the immune system. Nat Rev Immunol 2023; 23: 236-250. 
102. Wright SS, Kumari P, Fraile-Ágreda V, Wang C, Shivcharan S, Kappelhoff S, et al. Transplantation of gasdermin pores by extracellular vesicles propagates  pyroptosis to bystander cells. Cell 2025; 188: 280-291 
103. Pinzón-Fernández MV, Saavedra-Torres JS, López Garzón NA, Pachon-Bueno JS, Tamayo-Giraldo FJ, Rojas Gomez MC, et al. NLRP3 and beyond: Inflammasomes as central cellular hub and emerging therapeutic target in inflammation and disease. Front Immunol 2025; 16: 1624770. 
104. Qian C, Dong G, Yang C, Zheng W, Zhong C, Shen Q, et al. Broadening horizons: Molecular mechanisms and disease implications of endothelial-to-mesenchymal transition. Cell Commun Signal 2025; 23: 16.
105. Zavoriti A, Miossec P. Understanding cardiovascular events with JAK inhibitors: Tofacitinib reduces synovial and vascular inflammation but not the prothrombotic effects of inflammatory cytokines on endothelium. ACR Open Rheumatol 2025; 7: e11790.
106. Jung JU, Stippec S, Cobb M. Activation of WNK1 signaling through Piezo1. Proc Natl Acad Sci U S A 2025; 122: e2513155122.
107. Xie H, Ji J, Liu Z, Lu N, Wei Y, Zhou A, et al. Gαi1/3 signaling mediates IL-5-induced eosinophil activation and type 2 inflammation in eosinophilic chronic rhinosinusitis. Front Immunol 2025; 15: 146010.
108. Ye F, Huang J, Cheng X, Chen SC, Huang F, Huang WC, et al. AWT020: A novel fusion protein harnessing PD-1 blockade and selective IL-2  Cis-activation for enhanced anti-tumor immunity and diminished toxicity. Front Immunol 2025; 16: 1537466. 
109. Li J, Cui S, Li Y, Zhang C, Chang C, Jian F. Sirtuin1 in spinal cord injury: Regulatory mechanisms, microenvironment remodeling and therapeutic potential. CNS Neurosci Ther 2025; 31: e70244.
110. Zheng K, Wang S, Deng M, Luo Y, Li W, Zeng L, et al. Mechanisms and therapeutic strategies of macrophage polarization in intervertebral disc degeneration. JOR Spine 2025; 8: e70065. 
111. Xiang J, Li Y, Mei S, Ou Z, Wang L, Ke Y, et al. Novel diagnostic and therapeutic strategies based on PANoptosis for hepatocellular carcinoma. Cancer Biol Med 2025; 22: 928-939. 
112. Xiong B, Wang H, Song Y, Lan W, Li J, Wang F. Natural saponins and macrophage polarization: Mechanistic insights and therapeutic perspectives in disease management. Front Pharmacol 2025; 16: 1584035.
113. Nishida A, Andoh A. The role of inflammation in cancer: Mechanisms of tumor initiation, progression, and metastasis. Cells 2025; 14: 488. 
114. Li Y, Liu F, Cai Q, Deng L, Qin O, Zhang XH f, et al. Invasion and metastasis in cancer: molecular insights and therapeutic targets. Signal Transduct Target Ther 2025; 10: 57.
115. Rakib A, Mamun MA Al, Mandal M, Sinha P, Singh U. Obesity–cancer axis crosstalk: Molecular insights and therapeutic approaches. Acta Pharm Sin B 2025; 15: 2930-2944.
116. Zhang J, Lv S, Peng X, Liu H, Guo J, Liu Z, et al. CircERC1 facilitates chemoresistance through inhibiting pyroptosis and remodeling extracellular matrix in pancreatic cancer. Mol Cancer 2025; 24: 185.
117. Guo Y, Liu Q, Yang J, Gao Y, Liu Y. The role of stem cell-derived exosomes in regulating pyroptosis for disease therapy. Stem Cell Res Ther 2025; 16: 386. 
118. Borji A, Aram C, Ziyadloo F, Zadeh MR, Rouzbahani KA, Kazemi M, et al. Gene regulation by non-Coding RNAs in infertility: A mechanistic review. J Ovarian Res 2025; 18: 265.
119. Wang WL, Shih YT, Wei S, Chiu J. Impacts of aging and fluid shear stress on vascular endothelial metabolism and atherosclerosis development. J Biomed Sci 2025; 32: 83.
120. Shi S, Ou X, Liu C, Wen H, Ke J. Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment. Front Immunol 2025; 16: 1549276.
121. Deng H, Rukhlenko O, Joshi D, Hu X, Junk P, Tuliakova A, et al. cSTAR analysis identifies endothelial cell cycle as a key regulator of flow-dependent artery remodeling. Sci Adv 2025; 11: 2023.
122. Mandalà M. Oxidative stress and inflammation in uterine–vascular adaptation during pregnancy. Antioxidants 2025; 14: 1051.
123. Rannikko J, Turpin R, Boström P, Virtakoivu R, Harth C, Takeda A, et al. Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment. J Immunother Cancer 2025; 13: e011292.
124. Sarapultsev A, Komelkova M, Lookin O, Khatsko S, Zhdanov A, Fedorov S, et al. Zebrafish as a model organism for post-traumatic stress disorder: Insights into stress mechanisms and behavioral assays. Biology (Basel) 2025; 14: 939.
125. Petropoulos A, Stavropoulou E, Tsigalou C, Bezirtzoglou E. Microbiota gut–brain axis and autism spectrum disorder: Mechanisms and therapeutic perspectives. Nutrients 2025; 17: 2984.
126. Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y, et al. Tissue macrophages: Origin, heterogenity, biological functions, diseases and therapeutic targets. Signal Transduct Target Ther 2025; 10: 93.
127. Mulyani AT, Khairinisa M, Khatib A, Chaerunisaa A. Understanding stunting: Impact, causes, and strategy to accelerate stunting reduction—A narrative review. Nutrients 2025; 17: 2375.
128. Palley B, Martins JP, Bernardo H, Rossetti R. Integrating machine learning and digital twins for enhanced smart building operation and energy management: A systematic review. Urban Sci 2025; 9: 202.
129. Roka R, Figueiredo A, Vieira A, Cardoso C. A systematic review of sensitivity analysis in building energy modeling: Key factors influencing building thermal energy performance. Energies 2025; 18: 2375.
130. Wang Y, Guan QN, Zhang ZJ, Zhang YM. Interaction between endothelial injury and immune response in septic shock: from  basic research to clinical applications. Front Physiol 2025; 16: 1627008. 
131. Lee C, Kim MJ, Kumar A, Lee HW, Yang Y, Kim Y. Vascular endothelial growth factor signaling in health and disease: From molecular mechanisms to therapeutic perspectives. Signal Transduct Target Ther 2025; 10: 170. 
132. Lungu CN, Gurau G, Mehedinti MC. Pro-angiogenic bioactive molecules in vascular morphogenesis: integrating endothelial cell dynamics. Curr Issues Mol Biol 2025; 47: 851. 
133. Wolosowicz M, Prokopiuk S, Kaminski TW. Matrix metalloproteinase-9 (MMP-9) as a therapeutic target: Insights into  molecular pathways and clinical applications. Pharmaceutics 2025; 17: 1425. 
134. Liu Y, Guo Y, Wu X, Yan P, Wei Y. Neutrophil extracellular traps: Potential therapeutic targets of traditional  chinese medicine and natural products for cardiovascular diseases. Pharmaceuticals (Basel) 2026; 19: 183. 
135. Jiang M, Shao J, Lin K, Lin L, Yue S, Yan H, et al. SIRT3 regulates PDHA1 acetylation in HUVECs to modulate inflammation and pyroptosis under clinorotation. iScience 2025; 28: 113790.
136. Alhumaydhi FA, Anwar S. Extracellular vesicles in cancer: Mechanistic insights and clinical applications. Cancers (Basel) 2026; 18: 537. 
137. Bao Y, Yang X, Zhao P, Du X. Research advances on the role of programmed endothelial cell death in sepsis. Cell Death Discov 2025; 11: 426.
138. Cui C, Yang R, Chen H, Li D, Sun X, Wang Y, et al. Air toxins disorder the NF-kB Pathway leads to immune disorders and immune diseases in the human health. Ecotoxicol Environ Saf 2025; 302: 118474.
139. Izadpanah R, Izadpanah A, Alt EU. Dual faces of angiogenesis: Mechanisms and therapeutic applications. Biochim Biophys Acta Rev Cancer 2025; 1880: 189494.
140. Zhang J, Gao P, Chang WR, Song JY, An FY, Wang YJ, et al. The role of HIF-1α in hypoxic metabolic reprogramming in osteoarthritis. Pharmacol Res 2025; 213: 107649.
141. Dong Y, Li T, Fang B, Long D, Tian Y, Fu H. IL-1β+ lung-resident macrophages mediate endothelial dysfunction and acute lung injury in sepsis through immune-metabolic crosstalk. Cell Death Discov 2025; 12: 85.
142. Clements A, Casillas A, Flores C, Liou H, Toth R, Chauhan S, et al. Inhibition of PIM kinase in tumor-associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy. Cancer Immunol Res 2025; 17: 290.
143. Oyende Y, Taus L, Fatatis A. IL-1β in neoplastic disease and the role of its tumor-derived form in the progression and treatment of metastatic prostate cancer. Cancers (Basel) 2025; 17: 290.
144. Li H, Liu T, Shi X, Du H, Cai C, Yang D, et al. Mechanisms and therapeutic potential of pharmacological agents targeting inflammasomes. Biomed Pharmacother 2025; 189: 118164.
145. Rossetto RZ, De Oliveira Maciel S, Cardoso A. Relationship between purinergic signalling and oxidative stress in prostate cancer: Perspectives for future therapy. Crit Rev Oncol Hematol 2025; 209: 104675. 
146. Cimadamore A, Boixareu C, Sharp A, Beltran H, De Bono J. Novel therapeutic strategies for metastatic prostate cancer care. Eur Urol 2025; 88: 437-448.
147. Aram C, Barancheshmeh M, Alishvandi A, Khodabandehloo MH, Shirvani AH, Fotohi A, et al. Exploration of the protein and pharmacological landscape of monkeypox virus treatment: From entry point to end point. Mol Divers 2025; 12: 1-56.
148. Kwon W, Joung JY. Precision targeting in metastatic prostate cancer: Molecular insights to therapeutic frontiers. Biomolecules 2025; 15: 625.
149. Lu X, Sun Y, Zhang Z, Sun Z, Wang S, Xu E. Regulation of pyroptosis by natural products in ulcerative colitis: Mechanisms and therapeutic potential. Front Pharmacol 2025; 16: 1573684. 
150. Shi Y, Hu Y, Li J, Chen H, Zhong Q, Xiaoyan, et al. Inhibition of caspase-1 suppresses GSDMD-mediated peritoneal mesothelial cell pyroptosis and inflammation in peritoneal fibrosis. Small 2025;  21: e2409362.
151. Gu C, Wang D, Zhu S, Wang X, Tian X, Liao Y, et al. A pyroptosis radiosensitizer facilitates hypoxic tumor necrosis. Small 2025; 21: 2409594.
152. Boixareu C, Taha T, Venkadakrishnan V, De Bono J, Beltran H. Targeting the tumour cell surface in advanced prostate cancer. Nat Rev Urol 2025; 22: 569-589.
153. Liang C, Liu X, Yu J, Shi L, Wei W, Zhu Y, et al. Hypericin photoactivation induces triple-negative breast cancer cells pyroptosis by targeting the ROS/CALR/Caspase-3/GSDME pathway. J Adv Res 2025; 77: 669–688. 
154. Yadegari F, Asosheh A. A unified IoT architectural model for smart hospitals: Enhancing interoperability, security, and efficiency through clinical information systems (CIS). J Big Data 2025; 12: 149.
155. Kleandrova V, Cordeiro M, Speck-Planche A. In silico approach for antibacterial discovery: PTML modeling of virtual multi-strain inhibitors against Staphylococcus aureus. Pharmaceuticals 2025; 18: 196. 
156. Alatawi S, Alzahrani O, Alatawi F, Almazni I, Almotiri A, Almsned F. Identification of UBA7 expression downregulation in myelodysplastic neoplasm with SF3B1 mutations. Sci Rep 2025; 15: 10856. 
157. Stenger PL, Léopold A, Dinh K, Mournet P, Robert N, Drouin J, et al. Advancing biomonitoring of eDNA studies with the Anaconda R package: Integrating soil and One Health perspectives in the face of evolving traditional agriculture practices. PLoS One 2025; 20: e0311986.
158. Abo-Alian A, Youssef M, Badr N. A data-driven approach to prioritize MITRE ATT&CK techniques for active directory adversary emulation. Sci Rep 2025; 15: 27776.
159. Tanous O, Hosny N, Joseph S. Are we all post traumatic yet? a critical narrative review of trauma among arab refugees. Int J Soc Determ Heal Heal Serv 2025; 55: 341-351.
160. Prakash C, Mahar R. Chemical Profiling and quality assessment of food products employing magnetic resonance technologies. Foods 2025; 14: 2417.
161. Fazekas T, Miszczyk M, Giesen A, Kói T, Zattoni F, Rodriguez-Sanchez L, et al. Androgen receptor pathway inhibitor monotherapy in prostate cancer: Safety,  oncologic outcomes, and quality of life-a systematic review and meta-analysis. Eur Urol Focus 2026; 12: 109-130. 
162. Azad A, Kostos L, Agarwal N, Attard G, Davis I, Dorff T, et al. Combination therapies in locally advanced and metastatic hormone-sensitive prostate cancer. Eur Urol 2025; 4: 455-467.
163. Bastos D, Soares A, Schutz FAB, Cronemberger E, De Almeida Luz M, Martins S, et al. Androgen receptor pathway inhibitor therapy for advanced prostate cancer. JAMA Netw Open 2025; 8: 2454253.
164. Muniz M, Sartor O, Orme J, Koch R, Scharf Z, Heath E, et al. Outcomes for [177Lu]Lu-PSMA-617 with and without concurrent use of androgen receptor pathway inhibitors in patients with metastatic castration-resistant prostate cancer. Eur Urol Oncol 2025; 8: 1087-1093.
165. Huang X, Hu J. In silico discovery of novel androgen receptor inhibitors for prostate cancer therapy using virtual screening, molecular docking, and molecular dynamics simulations. Sci Rep 2025; 15: 29404.
166. Ibáñez C, Touris-Lores M, Montesa Á, López-Campos F, Ríos E, Usán P, et al. Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): Practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage. Expert Opin Drug Metab Toxicol 2025; 21: 625–636.
167. James N, Rush H, Nankivell M, Sehjal J, Mangar S, McPhail N, et al. Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform. J Clin Oncol 2025; 43: 5.
168. Galsky M, Autio K, Cabanski C, Wentzel K, Graff J, Friedlander T, et al. Clinical and translational results from PORTER, a multicohort phase I platform trial of combination immunotherapy in metastatic castration-resistant prostate cancer. Clin Cancer Res 2025; 31: 1463–1475.
169. Wang X, Jing J. Cancer immunotherapy in combination with radiotherapy and/or chemotherapy: Mechanisms and clinical therapy. MedComm 2025; 6: e70346. 
170. Hartley F, Ebert M, Cook A. Leveraging radiotherapy to improve immunotherapy outcomes: Rationale, progress and research priorities. Clin Transl Immunol 2025; 14: e70030.
171. Rai V. Immune checkpoint inhibitor therapy for prostate cancer: Present and future prospectives. Biomolecules 2025; 15: 751.
172. Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh M, Nabavi N, et al. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer 2025; 24: 136. 
173. Kwon W, Joung JY. T-cell engager therapy in prostate cancer: Molecular insights into a new frontier in immunotherapy. Cancers (Basel) 2025; 17: 1820.
174. Zhang L, Fu J, Liu X, Feng S, Leng YJ. The immune landscape of systemic inflammation in prostate cancer. Cancer Biol Med 2025; 22: 881-902. 
175. Xie Y, Liu F, Wu Y, Zhu Y, Jiang Y, Wu Q, et al. Inflammation in cancer: Therapeutic opportunities from new insights. Mol Cancer 2025; 24: 51. 
176. Liu R, Lu J, Liu J, Liao Y, Guo Y, Shi P, et al. Macrophages in prostate cancer: Dual roles in tumor progression and immune evasion. J Transl Med 2025; 23: 615.
177. Pei X, Liu L, Han Y. Advances in human microbiome and prostate cancer research. Front Immunol 2025; 16: 1576679. 
178. Colarusso C, Terlizzi M, Di Caprio S, Falanga A, D’Andria E, Di Villa Bianca R d’Emmanuele, et al. Conventional chemotherapy and inflammation: What is the role of the inflammasome in the tumor microenvironment? Biomedicines 2025; 13: 203.
179. Chen R, Zou J, Chen J, Zhong X, Kang R, Tang D. Pattern recognition receptors: Function, regulation and therapeutic potential. Signal Transduct Target Ther 2025; 10: 216.
180. Sharma M, Waterston A, Randolph CJ, Stark LE, Gravano DM, Colvin ME, et al. The ASC-c isoform as a modulator of inflammasome activation: Insights into molecular mechanisms and therapeutic applications. J Biol Chem 2026; 302: 111353. 
181. Garlanda C, Di Ceglie I, Jaillon S. IL-1 family cytokines in inflammation and immunity. Cell Mol Immunol 2025; 22: 1345-1362. 
182. Shua Y, Wang Q, Wang Y, Jiang C. Progress in small-molecule inhibitors of gasdermin D. Eur J Med Chem 2025; 300: 118171.
183. Chee YJ, Dalan R, Cheung C. The interplay between immunity, inflammation and endothelial dysfunction. Int J Mol Sci 2025; 26: 1708. 
184. Maiorano BA, Mercinelli C, Cigliola A, Tateo V, Gandaglia G, Briganti A, et al. Addition of androgen-receptor pathway inhibitors to standard of care in  metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Urol Oncol 2026; 44: 27-37. 
185. Bleve S, Nuzzo PV, Arham AB, Holmes A, Tagawa ST. Androgen receptor pathway signaling inhibitors in development for prostate cancer  therapy. Expert Opin Investig Drugs 2025; 34: 755-773. 
186. Liu Q, Zeng X, He Y, Zhou L, Tang Y, Liu S, et al. FLASH radiotherapy and immunotherapy synergy: Mechanisms, strategies, and clinical translation prospects. Front Immunol 2026; 17: 1788149. 
187. Qian X, Sun J, Li F, Xu L, Hu X, Dong N, et al. Inflammasomes as the molecular hub of cardiovascular-metabolic-immune comorbidity networks. Front Immunol 2025; 16: 1690443.
188. Li J, Zhang L, Zhan Y, Han X, Deng C. Molecular and multimodal biomarkers in Moyamoya disease: from pathogenic mechanisms to clinical translation. Eur J Med Res 2026; 31: 187.
189. Herrick W, Tran HL, Tomaino F, Beall B, Govindharajulu J, Esposito D, et al. Potent ferroptosis agent RSL3 induces cleavage of pyroptosis-specific gasdermins in cancer cells. Sci Rep 2025; 15: 25249. 
190. Wu S, Yao L, Zhang W, Chen P, Jiang J, Yao. Bioinformatics analysis and validation of novel biomarkers and competitive endogenous RNA networks involved in pyroptosis in diabetic nephropathy. Sci Rep 2025; 15: 5530.
191. Xu X, Lv X, Zeng R, Huang Z, Huang Z, Han B, et al. Elevated levels of IRF1 and CASP1 as pyroptosis-related biomarkers for intestinal epithelial cells in Crohn’s disease. Front Immunol 2025; 16: 1551547.
192. Yang S, Guan Y, Zheng C, Xia X, Xiaosheng, Jiang J. FOXO3-induced microRNA-128-3p promotes the progression of spinal cord injury in mice via regulating NLRP3 inflammasome-mediated pyroptosis. Front Immunol 2025; 16: 1526721.
193. Hu Y, Qi E, Yun C, Li X, Liu F, Cheng Z, et al. Photothermal therapy combined with a STING agonist induces pyroptosis, and gasdermin D could be a new biomarker for guiding the treatment of pancreatic cancer. J Transl Med 2025; 23: 271. 
194. Liu Z, Wang H, Yang C, Zhao X, Hui L, Song J, et al. Enhancing antitumor immunity via ROS-ERS and pyroptosis-induced immunogenic cell death in multiple myeloma. J Immunother Cancer 2025; 13: e011717. 
195. Dihlmann S, Kaduk C, Passek K, Spieler A, Böckler D, Peters A. Exploring circulating cell-free DNA as a biomarker and as an inducer of AIM2-inflammasome-mediated inflammation in patients with abdominal aortic aneurysm. Sci Rep 2025; 15: 20196. 
196. Xu Y, Chan MTJ, Yang M, Meng H, Chen CH. Time-resolved single-cell secretion analysis via microfluidics. Lab Chip 2025; 25: 1282-1295.
197. Yang X, Hong S, Yan T, Liu M, Liu M, Zhao J, et al. MiR‐146a engineered extracellular vesicles derived from mesenchymal stromal cells more potently attenuate ischaemia–reperfusion injury in lung transplantation. Clin Transl Med 2025; 15: e70298. 
198. Schiemer R, Grant J, Shafiee M, Phang S, Furniss D, Boitor R, et al. Infrared and raman spectroscopy of blood plasma for rapid endometrial cancer detection. Br J Cancer 2025; 133: 194-207.
199. Kim J, Schanzer N, Singh RS, Zaman M, Garcia-Medina J, Proszynski J, et al. DOGMA-seq and multimodal, single-cell analysis in acute myeloid leukemia. Int Rev Cell Mol Biol 2024; 390: 67-108.
200. Aghaee M, Ramirez AA, Alam Z, Ali R, Andrzejczuk M, Antipov A, et al. Interferometric single-shot parity measurement in InAs–Al hybrid devices. Nature 2025; 638: 651-655.
201. Wu J, Qian Y, Yang K, Zhang S, Zeng E, Luo D. Innate immune cells in vascular lesions: mechanism and significance of diversified immune regulation. Ann Med 2025; 57: 2453826.
202. Kushwaha R, Patel S, Yuvaraj K, Sharma P, Kumar A, Chakravarty S. Investigating molecular mechanisms in ischemic preconditioning-induced resiliency to severe acute global cerebral ischemia using a mouse model of chronic cerebral hypoperfusion. Cell Mol Neurobiol 2025; 45: 27.
203. Jensen L, Guo Z, Sun X, Jing X, Yang Y, Cao Y. Angiogenesis, signaling pathways, and animal models. Chin Med J (Engl) 2025; 138: 1153-1162. 
204. Kosuru R, Chrzanowska M. Divergent Functions of Rap1A and Rap1B in Endothelial Biology and Disease. Int J Mol Sci 2025; 26: 5372. 
205. Zhao X, Gu C, Wang M, Huang S, Gong X, Kang M, et al. Human neural progenitor cell-derived exosomes deliver miR- 100 - 5p targeting NOX4 mRNA to alleviate oxidative stress in acute ischemia injury. Mol Neurobiol 2025; 62: 12344-12359. 
206. Kong M, Zhai Y, Liu H, Zhang S, Chen S, Li W, et al. Insights into the mechanisms of angiogenesis in hepatoblastoma. Front Cell Dev Biol 2025; 13: 1535339.
207. Liu H, Wang S, Wang J, Guo X, Song Y, Fu K, et al. Energy metabolism in health and diseases. Signal Transduct Target Ther 2025; 10: 69.
208. Wawrzak-Pienkowska K, Pienkowski T, Tankiewicz-Kwedlo A, Ciborowski M, Kurek K, Pawlak D. Differences in treatment outcome between translational platforms in developing therapies for gastrointestinal cancers. Eur J Pharmacol 2025; 991: 177309. 
209. Allgayer H, Mahapatra S, Mishra B, Swain B, Saha S, Khanra S, et al. Epithelial-to-mesenchymal transition (EMT) and cancer metastasis: The status quo of methods and experimental models 2025. Mol Cancer 2025; 24: 167. 
210. Liu M, Yang X. Patient-derived xenograft models: Current status, challenges, and innovations in cancer research. Genes Dis 2025; 12: 101520.
211. Ciringione A, Rizzi F. Facing the challenge to mimic breast cancer heterogeneity: Established and emerging experimental preclinical models integrated with omics technologies. Int J Mol Sci 2025; 26: 4572.
212. Mohapatra R, Leist M, Von Aulock S, Hartung T. Guidance for good in vitro reporting standards (GIVReSt) - A draft for stakeholder discussion and background documentation. ALTEX 2025; 42: 376-396.
213. Langan L, Baettig C, Cole A, Lovin L, Scarlett K, Wronski A, et al. Experimental reporting of fish transcriptomic responses in environmental toxicology and ecotoxicology. Environ Toxicol Chem 2025; 44: 2580-2598.
214. Karle A, Kopp K, Seward R, Tourdot S, Ackaert C, Gutknecht M, et al. MAPPs assays for non-clinical immunogenicity risk assessment: Best practices recommended by the European immunogenicity platform. Front Immunol 2025; 16: 1690101.
215. Bustin S, Kirvell S, Nolan T, Mueller R, Shipley G. When two-fold is not enough: Quantifying uncertainty in low-copy qPCR. Int J Mol Sci 2025; 26: 7796.
216. Jia Z, Liu Y, Qu S, Li W, Gao L, Dong L, et al. Evaluative methodology for HRD testing: Development of standard tools for consistency assessment. Genomics Proteomics Bioinformatics 2025; 23: 017. 
217. Yücel M, Luke R, Mesquita R, Von Lühmann A, Mehler D, Lührs M, et al. fNIRS reproducibility varies with data quality, analysis pipelines, and researcher experience. Commun Biol 2025; 8: 1149. 
218. Galbo P, Klees R, Burgher B, Miles K, Morrison C, Glenn S. A comprehensive guide to achieving new york state clinical laboratory evaluation program approval for next-generation sequencing assays. J Mol Diagn 2025; 27: 485-501.
219. Xia CL, Liang F, Li JX, Qu Y, Zhang W, Ou S, et al. Identification of the pyroptosis, apoptosis, and necroptosis (PANoptosis)  involved in osteogenic differentiation inhibition impaired by tumor necrosis factor-α. Eur J Med Res 2025; 30: 541. 
220. Madsen PA, Jerez-Bogotá K, Vodolazska D, Lauridsen C. Comparative study of cytokine measurements in blood plasma and serum, and saliva of juvenile pigs during experimentally induced acute inflammation. Vet Sci 2026; 13: 68. 
221. Rozario P, Lim YS, Ding SLS, Firdaus MJ, Wearne S, Wong BHS, et al. IFNγ priming enables NLRP3 inflammasome activation in human keratinocytes in vitro. J Invest Dermatol 2025; 146: 1851-1866.
222. Lee C, Hyun S, Rhee I. Flow cytometric and multimodal detection of ASC speck formation in THP-1 monocytes and murine macrophages following canonical inflammasome activation. J Anal Sci Technol 2025; 16: 34.
223. Wells SB, Rainbow DB, Mark M, Szabo PA, Ergen C, Caron DP, et al. Multimodal profiling reveals tissue-directed signatures of human immune cells altered with age. Nat Immunol 2025; 26: 1612-1625.
224. Skill NJ, Avanzino K, Bren-Mattison Y, Boudreaux JP, Thiagarajan R, Maluccio M. The vascular density/angiogenesis marker CD31/PECAM1 does not correlate with  overall survival in neuroendocrine tumors. J Gastrointest Cancer 2026; 57: 4. 
225. Li B, Cao H, Takase H, Allu SR, Wu Y, Fu B, et al. Mismatch between oxygen delivery and consumption in the cerebral watershed during  subacute global hypoperfusion. Exp Neurol 2026; 399: 115666. 
226. Sharka I, Panichella G, Grigoratos C, Muca M, De Gori C, Keilberg P, et al. Myocardial perfusion imaging with cardiovascular magnetic resonance in nonischemic cardiomyopathies: An in-depth review of techniques and clinical applications. Medicina 2025; 61: 875. 
227. MacPhee CA, Natale B V, Noordhof C, Wang S, Lima PDA, Natale DRC. The regulation of placental pericyte function through transforming growth factor β-1 signalling. Sci Rep 2025; 15: 36668.
228. Lei Y, Xiao T, Hu X, Lin H. Advanced drug delivery strategies for overcoming biological barriers: Tumor microenvironment and blood–brain barrier. Drugs R D 2026; 26: 1-30.
229. Behrens LMP, Fernandes G da S, Gonçalves GF, Nunes FVM, Weimer RD, Moreira JCF, et al. Limitations and opportunities in multi-omics integration for neurodevelopmental, neurodegenerative and psychiatric disorders: A systematic review. Neuroscience 2026; 599: 76-93.
230. Wang Q, Yuan F, Zuo X, Li M. Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: A cutting-edge tool for advancing personalised treatments. Cell Death Discov 2025; 11: 222.
231. Xiao Y, Li Y, Jing X, Weng L, Liu X, Liu Q, et al. Organoid models in oncology: Advancing precision cancer therapy and vaccine development. Cancer Biol Med 2025; 22: 903-927.
232. Zhao X, Gao J, Liu Y, Shi Y, Zhang M, Zhang C, et al. Application and challenges of tumor organoid technology in precision immunotherapy. Front Immunol 2025; 16: 723995.
233. Bridgeford EW, Powell M, Kiar G, Noble S, Chung J, Panda S, et al. When no answer is better than a wrong answer: A causal perspective on batch  effects. Imaging Neurosci (Camb) 2025; 3: 458. 
234. Choi J, Chae H. A unified framework for correcting batch effects and integrating multi-omics data. Sci Rep 2026; 16: 12341.
235. Fang D, Min W. SpaCross deciphers spatial structures and corrects batch effects in multi-slice spatially resolved transcriptomics. Commun Biol 2025; 8: 1393.
236. Saadh M, Muhammad FA, Albadr RJ, Sanghvi G, Jyothi S, Kundlas M, et al. Inflammasomes and cardiovascular disease: Linking inflammation to cardiovascular pathophysiology. Scand J Immunol 2025; 101: e70020.
237. Versnjak J, Kuehne T, Fahjen P, Jovanovic N, Loeber U, Schiattarella G, et al. Deep phenotyping of heart failure with preserved ejection fraction through multi‐omics integration. Eur J Heart Fail 2025; 27: 3243–3259. 
238. Jäger J, Thon M, Schimek K, Marx U, Gibbs S, Koning J. Differential biomarker expression of blood and lymphatic vasculature in multi-organ-chips. Sci Rep 2025; 15: 14492. 
239. Lu Y, Cheng L, Xiong Y, Huang C, Liu Z, Shen C, et al. NLRP3 inflammasome in vascular dementia: Regulatory mechanisms, functions, and therapeutic implications: A comprehensive review. CNS Neurosci Ther 2025; 31: e70403.
240. Zhao YH, Cai YX, Pan ZY, Tang F, Chao, Wang ZF, et al. Novel CHI3L1‐associated angiogenic phenotypes define glioma microenvironments: Insights from multi‐omics integration. Cancer Sci 2025; 116: 1433–1448.
241. Hoy S. Mirdametinib: First approval. Drugs 2025; 85: 977-984.
242. Munteanu I, Novaconi RC, Merce A, Dima C, Falnita L, Manzur AR, et al. Cardiac hemangiomas: A five-year systematic review of diagnosis, treatment, and outcomes. Cancers (Basel) 2025; 17: 1532.
243. Tian H, Wan C. Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: A systematic review and meta-analysis. World J Surg Oncol 2025; 23: 126. 
244. Christensen A, IIkjær C, Laustrup T, Sejer E, Rønnøw C, Døssing K, et al. Ultrasound‐guided nerve blocks improve success rate of closed reduction of colles’ fractures: A randomised controlled trial. Acta Anaesthesiol Scand 2025; 69: e70063.
245. Borji AH, Rahimi M, Alishvandi A, Barancheshmeh M, Aram C, Khodabandehloo MH, et al. Root-cause immunotherapy: AI-guided TCR strategies to eradicate leukemic stem cells in myeloid malignancies. Netw Model Anal Heal Informatics Bioinforma 2026; 15: 103.
246. Lin K, Eyal S, Demarchi I, Ben-Shushan T, Auvin S, Khoo C, et al. Prioritizing questions and topics for the development of guidelines and consensus-based recommendations supported by ILAE: A scoping review and proposal of prioritization criteria. Epilepsia 2025; 66: 1406-1416.
247. Zhang J, Peng J, Yu C, Ning Y, Lin W, Ni M, et al. Prioritization of potential drug targets for diabetic kidney disease using integrative omics data mining and causal inference. J Pharm Anal 2025; 15: 101265.
248. Al-Rawashdeh TA, Al’azzeh F, Al-Tarawneh F. An analytical hierarchy process-based technique for software requirements prioritization. IEEE Access 2025; 13: 50603-50610. 
249. Yang M, Chen X, Zhang M, Zhang X, Xiao D, Xu H, et al. hUC-MSC preserves erectile function by restoring mitochondrial mass of penile smooth muscle cells in a rat model of cavernous nerve injury via SIRT1/PGC-1a/TFAM signaling. Biol Res 2025; 58: 8.
250. Chen W, Zhi X, Hu J, Yu L, Han Q, Zhang W. Genetic algorithm-based weighted constraint target band selection for hyperspectral target detection. Remote Sens 2025; 17: 673.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 19 July 2026